Breakthrough Vertigo Treatment: Combination Therapy Outperforms Standard Care with Fewer Side Effects

What is the Promise of a New Vertigo Treatment Approach?

Combination therapy using diphenhydramine and sodium bicarbonate showed superior efficacy in treating acute peripheral vertigo compared to diphenhydramine alone in a randomized clinical trial conducted in Taiwan. The study, involving 222 patients, demonstrated significant vertigo symptom reduction with the combination approach, particularly among younger male patients without prior vertigo history, while reducing the need for rescue medications.

The trial, conducted at National Taiwan University Hospital from January to November 2023, compared three treatment arms: standard diphenhydramine (30mg IV), sodium bicarbonate alone (66.4 mEq IV), and a combination of both medications. The primary outcome measured changes in vertigo severity using a visual analog scale (VAS) from baseline to 60 minutes post-treatment. The combination therapy group showed a mean VAS score reduction of 5.6 points compared to 4.4 points in the diphenhydramine-only group (p=0.01), representing a statistically significant improvement.

How Does the Combination Therapy Challenge Traditional Management?

While antihistamines like diphenhydramine have long been the standard treatment for acute peripheral vertigo in emergency departments, they frequently cause sedation and increased fall risk. Sodium bicarbonate, though widely used for vertigo treatment in Eastern countries like Taiwan and Japan, has limited documentation in Western medical literature. The researchers noted several potential mechanisms for sodium bicarbonate's effectiveness, including inhibition of neural activity in the medial vestibular nucleus, reduced amygdala activation, and increased cochlear and cerebral blood flow based on previous animal and human studies.

What Do Experts Say About the Therapy's Safety Profile?

A key secondary finding revealed that while more than 70% of patients receiving diphenhydramine experienced lethargy after administration, sodium bicarbonate demonstrated a superior safety profile regarding sedation. Dr. Chang-Chih Shih, the study's lead author, commented: "This provides an important alternative for patients who need to drive or work after treatment, as well as for ED patients with higher fall risks." The combination therapy group also required significantly less rescue therapy (17.8%) compared to the diphenhydramine-only group (46.7%).

The study did report that sodium bicarbonate administration was associated with more injection discomfort compared to diphenhydramine alone. However, researchers suggested that slow infusion administration might reduce this risk. No other severe adverse events were recorded during the trial, and all participants were followed for 14 days post-treatment.

What Are the Study’s Limitations and Future Research Directions?

The research team emphasized that these findings represent the first double-blinded randomized clinical trial demonstrating sodium bicarbonate's effectiveness for vertigo treatment in English-language literature. They acknowledged several limitations, including the study's single-center design and daytime-only recruitment, which may affect generalizability. The researchers called for further multicenter studies to validate their findings and determine which specific subtypes of peripheral vertigo might benefit most from sodium bicarbonate treatment.

Emergency department length of stay was also slightly shorter in the combination therapy group (median 2.0 hours) compared to the diphenhydramine group (median 2.3 hours), though this difference narrowly missed statistical significance after correction for multiple comparisons. This finding could have operational implications for busy emergency departments seeking to optimize patient flow.

How Does This Innovation Stand Out in the Industry?

Industry Context: This study represents an important contribution to emergency medicine pharmacotherapy by offering a potentially safer alternative for vertigo management. As healthcare systems globally seek treatments with fewer adverse effects and shorter observation requirements, combination approaches that reduce sedation while maintaining or improving efficacy could gain significant traction. The repurposing of sodium bicarbonate, an inexpensive and widely available medication, also aligns with cost-containment initiatives in emergency care settings.

Summary

A randomized clinical trial conducted at National Taiwan University Hospital has demonstrated that combination therapy using diphenhydramine and sodium bicarbonate provides superior efficacy in treating acute peripheral vertigo compared to diphenhydramine alone. The study, which enrolled 222 patients between January and November 2023, showed that the combination approach achieved a mean vertigo severity reduction of 5.6 points on the visual analog scale compared to 4.4 points with diphenhydramine alone, representing a statistically significant improvement. Notably, the combination therapy demonstrated a markedly better safety profile, with significantly reduced sedation compared to diphenhydramine monotherapy, where over 70% of patients experienced lethargy. The combination group also required substantially less rescue medication, with only 17.8% needing additional treatment compared to 46.7% in the diphenhydramine-only group. While sodium bicarbonate has been widely used for vertigo treatment in Eastern countries like Taiwan and Japan, this represents the first double-blinded randomized clinical trial documenting its effectiveness in English-language medical literature. The researchers noted that sodium bicarbonate may work through multiple mechanisms including inhibition of neural activity in the medial vestibular nucleus, reduced amygdala activation, and increased cochlear and cerebral blood flow. The study's findings suggest particular benefits for younger male patients without prior vertigo history and offer an important alternative for patients who need to maintain alertness after treatment or have elevated fall risks. Although sodium bicarbonate administration was associated with more injection discomfort, researchers indicated that slow infusion could mitigate this issue. The research team acknowledged limitations including the single-center design and daytime-only recruitment, calling for further multicenter studies to validate the findings and identify which specific peripheral vertigo subtypes might benefit most from this treatment approach.